Why don't GLP‑1 obesity drugs work for everyone?
AI Summary
The article examines why GLP-1 obesity drugs such as Ozempic and Wegovy do not work equally well for everyone. These semaglutide-based treatments affect blood sugar, appetite, and body weight and are now widely used in obesity care.
Medications like Ozempic and Wegovy, which contain semaglutide—a GLP‑1 receptor agonist that helps regulate blood sugar, appetite and body weight—have become household names and important pillars in obesity management for the medical profession.